| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 02/12/2024 | 14:39 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section 12(g)] | NASDAQ:EXAI | Exscientia PLC |
| 23/11/2024 | 02:00 | Edgar (US Regulatory) | Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] | NASDAQ:EXAI | Exscientia PLC |
| 20/11/2024 | 16:01 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:EXAI | Exscientia PLC |
| 20/11/2024 | 15:20 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:EXAI | Exscientia PLC |
| 20/11/2024 | 13:00 | GlobeNewswire Inc. | Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | NASDAQ:EXAI | Exscientia PLC |
| 24/10/2024 | 22:00 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:EXAI | Exscientia PLC |
| 17/10/2024 | 03:49 | Business Wire | Exscientia franchit des étapes importantes pour deux de ses programmes dans le cadre de sa collaboration avec Sanofi | NASDAQ:EXAI | Exscientia PLC |
| 17/10/2024 | 03:35 | Business Wire | Exscientia erreicht Meilensteine für zwei Programme im Rahmen der Zusammenarbeit mit Sanofi | NASDAQ:EXAI | Exscientia PLC |
| 16/10/2024 | 13:00 | Business Wire | Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration | NASDAQ:EXAI | Exscientia PLC |
| 09/10/2024 | 21:25 | Business Wire | Exscientia präsentiert auf der ENA 2024 neue präklinische Daten für KI-gestützte LSD1- und MALT1-Inhibitoren | NASDAQ:EXAI | Exscientia PLC |
| 09/10/2024 | 21:25 | Business Wire | Exscientia présentera de nouvelles données précliniques pour les inhibiteurs de la LSD1 et du MALT1 conçus par l'IA à l'ENA 2024 | NASDAQ:EXAI | Exscientia PLC |
| 09/10/2024 | 13:00 | Business Wire | Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024 | NASDAQ:EXAI | Exscientia PLC |
| 30/08/2024 | 14:57 | Edgar (US Regulatory) | Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] | NASDAQ:EXAI | Exscientia PLC |
| 28/08/2024 | 18:11 | Business Wire | Exscientia wird auf der 22nd Annual Global Healthcare Conference Präsentation durchführen | NASDAQ:EXAI | Exscientia PLC |
| 28/08/2024 | 18:11 | Business Wire | Exscientia participera à la 22e conférence annuelle de Morgan Stanley sur les soins médicaux dans le monde | NASDAQ:EXAI | Exscientia PLC |
| 28/08/2024 | 13:00 | Business Wire | Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference | NASDAQ:EXAI | Exscientia PLC |
| 15/08/2024 | 13:00 | Business Wire | Exscientia Business Update for Second Quarter and First Half 2024 | NASDAQ:EXAI | Exscientia PLC |
| 09/08/2024 | 11:44 | IH Market News | TSMC July Revenue Surges 45%, Nasdaq Accelerates Penny Stock Delistings, Moody’s Downgrades Intel to BAA1, and More | NASDAQ:EXAI | Exscientia PLC |
| 08/08/2024 | 13:39 | GlobeNewswire Inc. | Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities | NASDAQ:EXAI | Exscientia PLC |
| 18/07/2024 | 18:36 | Business Wire | Exscientia erwirbt volle Rechte an potenziellem CDK7-Inhibitor der Spitzenklasse vor der Veröffentlichung von Phase-1-Dosis-Eskalationsdaten | NASDAQ:EXAI | Exscientia PLC |
| 18/07/2024 | 16:20 | Business Wire | Exscientia acquiert les droits complets d’un inhibiteur potentiel de CDK7, le meilleur de sa catégorie, avant la publication des données de dose croissante de phase 1 | NASDAQ:EXAI | Exscientia PLC |
| 18/07/2024 | 13:00 | Business Wire | Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout | NASDAQ:EXAI | Exscientia PLC |
| 10/07/2024 | 23:44 | Business Wire | Exscientia lance une plateforme AWS optimisée par l'IA pour promouvoir la découverte de médicaments | NASDAQ:EXAI | Exscientia PLC |
| 10/07/2024 | 21:13 | Business Wire | Exscientia bringt KI-gestützte AWS-Plattform zur Verbesserung der Arzneimittelforschung auf den Markt | NASDAQ:EXAI | Exscientia PLC |
| 10/07/2024 | 13:00 | Business Wire | Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery | NASDAQ:EXAI | Exscientia PLC |
| 25/06/2024 | 11:45 | PR Newswire (US) | EXAI LAWSUIT ALERT: The Gross Law Firm Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming Deadline | NASDAQ:EXAI | Exscientia PLC |
| 20/06/2024 | 11:45 | PR Newswire (US) | Exscientia plc Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAI | NASDAQ:EXAI | Exscientia PLC |
| 17/06/2024 | 11:45 | PR Newswire (US) | Shareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action - Contact The Gross Law Firm to Learn More | NASDAQ:EXAI | Exscientia PLC |
| 10/06/2024 | 11:45 | PR Newswire (US) | June 25, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against EXAI | NASDAQ:EXAI | Exscientia PLC |
| 06/06/2024 | 22:16 | Business Wire | Exscientia ernennt neue Führungskräfte zur Stärkung der Auswirkungen integrierter Technologien und um den Schwerpunkt auf klinische Entwicklungskompetenz in der Onkologie zu richten | NASDAQ:EXAI | Exscientia PLC |